Medical Device Manufacturers Are the Underserved MBE Opportunity in Your Territory

The MBE conversation in sales and marketing circles is dominated by aerospace and defense. The prime contractor MBD mandates, the AS9100D requirements, the ITAR complexity — these are the reference cases that get written up and presented at trade shows.

What gets significantly less attention is medical devices. And that is a problem — because the medical device sector has MBE requirements that are in many ways more demanding than aerospace, a regulatory framework that creates structural urgency, and a buyer profile that is actively underserved by the current MBE solution provider landscape.

21 CFR Part 820 (FDA Quality System Regulation, now harmonized with ISO 13485:2016) requires medical device manufacturers to maintain complete design history files, device master records, and complaint records with full traceability from design input through production output and post-market surveillance.

In a 2D drawing-based workflow, assembling this traceability documentation requires manual cross-referencing across design documents, manufacturing instructions, inspection records, and service records. In an MBE workflow with a properly implemented digital thread, this documentation assembles itself — because every artifact is linked to every other artifact through the model.

The FDA’s enforcement of 483 observations (inspection findings) related to design control and record traceability has intensified since the harmonization with ISO 13485. Medical device manufacturers who cannot demonstrate clean, automated traceability are facing increasing regulatory risk.

“A medical device manufacturer’s design history file is not a compliance document. It is a litigation defense. The cost of getting it wrong is measured in product liability exposure, not just audit findings.”

Medical device inspection has specific requirements that align directly with QIF’s capabilities. First-article inspection (FAI) under AS9102 or equivalent customer requirements involves dimensional measurement of every feature on a new part design — and the results must be traceable to the drawing or 3D model that specifies them.

QIF’s measurement result schema includes fields for design reference, revision level, FAI lot identification, equipment calibration records, and statistical summaries — all of which are required elements of a compliant FAI package. A QIF-native FAI workflow eliminates the manual assembly of FAI documentation and the transcription errors that accompany it.

For a medical device manufacturer producing 50 to 200 unique part numbers per year, each requiring FAI, the labor cost of manual FAI documentation is substantial. Quantify it and you have a business case.

The MBE buyer in a medical device company is different from the aerospace buyer. In aerospace, the quality manager is often the primary champion. In medical devices, the regulatory affairs manager is frequently the primary driver — because the regulatory exposure is the primary urgency.

This person sits at the intersection of quality, engineering, and regulatory compliance. They are reading FDA warning letters. They are tracking 483 observation trends across the industry. They are attending RAPS (Regulatory Affairs Professionals Society) conferences, not manufacturing trade shows.

Your content and outreach strategy needs to be present in their information environment, not just in the manufacturing quality space. A white paper titled “How MBD and QIF support ISO 13485 design control requirements” reaches this buyer where aerospace-focused MBE content does not.

• Contact regulatory affairs managers and quality assurance directors at Class II and Class III medical device manufacturers in your territory
• Ask about their current design history file assembly process and how long it takes to prepare for an FDA inspection
• Ask whether they have received any 483 observations related to design control or record traceability in the past three audit cycles
• Position your offering as “FDA-ready design traceability infrastructure” rather than “quality inspection software”
• Offer a complimentary design control traceability assessment as a discovery engagement — it surfaces the gaps that create urgency

KEY TAKEAWAY  Medical device manufacturers have demanding MBE and QIF requirements driven by FDA regulatory risk. They are underserved by the current MBE solution provider landscape — and the regulatory urgency creates a sales environment that does not require inertia-breaking.

2BMobile → 2BMobile builds vertical market strategies and content for solution providers targeting medical device manufacturers with MBE and quality data solutions. Talk to us about your medical device go-to-market.